Skip to main content
. 2025 Jan 10;11:1497529. doi: 10.3389/fnut.2024.1497529

Table 3.

Weighted logistic regression analysis of the connection between METS-VF and HUA.

aModel 1 bModel 2 cModel 3
Characteristic OR 95% CI p-value OR 95% CI p-value OR 95% CI p-value
Before PSM
Continuous 3.39 2.96, 3.88 <0.001 4.34 3.64, 5.17 <0.001 3.51 2.88, 4.27 <0.001
dQuartile
Q1 Ref Ref Ref
Q2 2.19 1.68, 2.86 <0.001 2.48 1.91, 3.23 <0.001 2.18 1.65, 2.89 <0.001
Q3 4.19 3.26, 5.38 <0.001 5.36 4.13, 6.96 <0.001 4.32 3.24, 5.76 <0.001
Q4 6.37 5.08, 7.98 <0.001 8.82 6.68, 11.6 <0.001 6.07 4.39, 8.38 <0.001
P for trend <0.001 <0.001 <0.001
After PSM
Continuous 1.91 1.64, 2.23 <0.001 2.48 2.05, 2.99 <0.001 2.90 2.36, 3.58 <0.01
dQuartile
Q1 Ref Ref Ref
Q2 1.42 1.03, 1.97 0.033 1.57 1.15, 2.16 0.005 1.72 1.24, 2.37 0.001
Q3 2.27 1.69, 3.04 <0.001 2.74 2.03, 3.71 <0.001 3.28 2.39, 4.50 <0.001
Q4 2.51 1.91, 3.29 <0.001 3.64 2.62, 5.05 <0.001 4.53 3.17, 6.46 <0.001
P for trend <0.001 <0.001 <0.001
a

Model 1: adjusted for no covariates.

b

Model 2: adjusted for age, gender, and race.

c

Model 3: adjusted for age, gender, race, education level, marital status, PIR, smoking, alcohol consumption, hypertension, diabetes, hyperlipidemia, CKD, CVD, physical activity, diuretic use, energy intake, ALT, and AST.

d

METS-VF quartiles: Q1: ≤5.75, Q2: 5.75–6.26, Q3: 6.26–6.62, Q4: >6.62.

HUA: hyperuricemia, METS-VF: Metabolic Score for Visceral Fat, OR: odds ratio, CI: confidence interval, PSM: propensity score matching, PIR: income-to-poverty ratio, CKD: chronic kidney disease, CVD: cardiovascular disease, AST, aspartate aminotransferase; ALT, alanine aminotransferase, Q: quartile.